Amedeo Smart

Free Medical Literature Service



Ovarian Neoplasms

  Free Subscription

Articles published in
PLoS One
    January 2024
  1. YOO MY, Woo KJ, Kang SY, Moon BS, et al
    Efficacy of preoperative lymphoscintigraphy in predicting surgical outcomes of lymphaticovenous anastomosis in lower extremity lymphedema: Clinical correlations in gynecological cancer-related lymphedema.
    PLoS One. 2024;19:e0296466.
    >> Share

  2. WANG G, Fu J, Liu M, Zheng Q, et al
    CXC chemokines: Potential biomarker and immunotherapeutic target for uterine corpus endometrial carcinoma.
    PLoS One. 2024;19:e0277872.
    >> Share

  3. Expression of Concern: Minocycline Suppresses Interleukine-6, Its Receptor System and Signaling Pathways and Impairs Migration, Invasion and Adhesion Capacity of Ovarian Cancer Cells: In Vitro and In Vivo Studies.
    PLoS One. 2024;19:e0298444.
    >> Share

  4. YONG CM, Yehgambaram PAP, Lee SWH
    Cost-effectiveness analysis of olaparib maintenance therapy for BRCA mutation ovarian cancer in the public sector in Malaysia.
    PLoS One. 2024;19:e0298130.
    >> Share

  5. DING H, Hu B, Guo R
    Comprehensive analysis of single cell and bulk data develops a promising prognostic signature for improving immunotherapy responses in ovarian cancer.
    PLoS One. 2024;19:e0298125.
    >> Share

    January 2023
  6. YOSHIDA-COURT K, Karpinets TV, Mitra A, Solley TN, et al
    Immune environment and antigen specificity of the T cell receptor repertoire of malignant ascites in ovarian cancer.
    PLoS One. 2023;18:e0279590.
    >> Share

  7. HOSSAIN MA, Sohel M, Rahman MH, Hasan MI, et al
    Bioinformatics and In silico approaches to identify novel biomarkers and key pathways for cancers that are linked to the progression of female infertility: A comprehensive approach for drug discovery.
    PLoS One. 2023;18:e0265746.
    >> Share

  8. CARMICHAEL MM, Alchaar I, Davis KA, Krevosky MK, et al
    The small heat shock protein alphaB-Crystallin protects versus withaferin A-induced apoptosis and confers a more metastatic phenotype in cisplatin-resistant ovarian cancer cells.
    PLoS One. 2023;18:e0281009.
    >> Share

  9. ENGEVIK KA, Engevik MA, Engevik AC
    Bioinformatics reveal elevated levels of Myosin Vb in uterine corpus endometrial carcinoma patients which correlates to increased cell metabolism and poor prognosis.
    PLoS One. 2023;18:e0280428.
    >> Share

  10. JANG YS, Kim TW, Ryu JS, Kong HJ, et al
    Upregulation of programmed death ligand-1 in tumor-associated macrophages affects chemotherapeutic response in ovarian cancer cells.
    PLoS One. 2023;18:e0277285.
    >> Share

  11. HAWARDEN A, Price M, Russell B, Wilson G, et al
    A three protein signature fails to externally validate as a biomarker to predict surgical outcome in high-grade epithelial ovarian cancer.
    PLoS One. 2023;18:e0281798.
    >> Share

  12. JLASSI A, Manai M, Morjen M, Sahraoui G, et al
    VISTA+/CD8+ status correlates with favorable prognosis in Epithelial ovarian cancer.
    PLoS One. 2023;18:e0278849.
    >> Share

  13. EBRING C, Marlin R, Macni J, Vallard A, et al
    Type II endometrial cancer: Incidence, overall and disease-free survival in Martinique.
    PLoS One. 2023;18:e0278757.
    >> Share

  14. NUNES PEREIRA P, Francoise Derchain S, Yoshida A, Hoelz de Oliveira Barros R, et al
    Diffusion-weighted magnetic resonance sequence and CA125/CEA ratio can be used as add-on tools to ultrasound for the differentiation of ovarian from non-ovarian pelvic masses.
    PLoS One. 2023;18:e0283212.
    >> Share

  15. GOLDSBURY DE, Vassallo A, Weber MF, Steinberg J, et al
    Health services costs for ovarian cancer in Australia: Estimates from the 45 and Up Study.
    PLoS One. 2023;18:e0282851.
    >> Share

  16. KIM NK, Suh DH, Kim K, Kim YB, et al
    Feasibility of extended cycles of neoadjuvant chemotherapy in patients with advanced ovarian cancer in terms of prognosis and surgical outcomes.
    PLoS One. 2023;18:e0284753.
    >> Share

  17. LOPACINSKA-JORGENSEN J, Petersen PHD, Oliveira DVNP, Hogdall CK, et al
    Strategies for data normalization and missing data imputation and consequences for potential diagnostic microRNA biomarkers in epithelial ovarian cancer.
    PLoS One. 2023;18:e0282576.
    >> Share

  18. Expression of Concern: Neoadjuvant chemotherapy versus primary debulking surgery in advanced epithelial ovarian cancer: A meta-analysis of peri-operative outcome.
    PLoS One. 2023;18:e0285545.
    >> Share

  19. WU X, Lu W, Jiang C, Zhang D, et al
    Effect of ERCC1 polymorphisms on the response to platinum-based chemotherapy: A systematic review and meta-analysis based on Asian population.
    PLoS One. 2023;18:e0284825.
    >> Share

  20. ANCHOORI RK, Anchoori V, Lam B, Tseng SH, et al
    Development and anticancer properties of Up284, a spirocyclic candidate ADRM1/RPN13 inhibitor.
    PLoS One. 2023;18:e0285221.
    >> Share

  21. LIU H, Ma S, Chen X, Wu H, et al
    Diagnostic accuracy of the Copenhagen Index in ovarian malignancy: A meta-analysis.
    PLoS One. 2023;18:e0286650.
    >> Share

  22. CHEN B, Lu X, Zhou Q, Chen Q, et al
    PAXIP1-AS1 is associated with immune infiltration and predicts poor prognosis in ovarian cancer.
    PLoS One. 2023;18:e0290031.
    >> Share

  23. MOATAMED NA, Vahdatshariatpanahi S, Gjertson DW, Sachs CR, et al
    Androgen receptor and its correlation with estrogen and progesterone receptors, aimed for identification of cases for future anti-androgen therapy in endometrial cancers.
    PLoS One. 2023;18:e0291361.
    >> Share

  24. MUHAMMAD S, Azwan RJ, Rita RS, Susanti R, et al
    The Role of Interleukin 6 (IL6), Cancer Antigen-125 (CA-125), and Human Epididymis Protein 4 (HE4) to predict tumor resectability in the advanced epithelial ovarian cancer patients.
    PLoS One. 2023;18:e0292282.
    >> Share

  25. LEE B, Chang SJ, Kwon BS, Son JH, et al
    Impact of PARP inhibitor maintenance therapy in newly diagnosed advanced epithelial ovarian cancer: A meta-analysis.
    PLoS One. 2023;18:e0294647.
    >> Share

  26. ROBERTSON SE, Yasukawa M, Marchion DC, Xiong Y, et al
    Prevalence of viral DNA in high-grade serous epithelial ovarian cancer and correlation with clinical outcomes.
    PLoS One. 2023;18:e0294448.
    >> Share

  27. Retraction: SOX2 Enhances the Migration and Invasion of Ovarian Cancer Cells via Src Kinase.
    PLoS One. 2023;18:e0295163.
    >> Share

  28. TAO F, Ruan S, Liu W, Wang L, et al
    Correction: Fuling Granule, a Traditional Chinese Medicine Compound, Suppresses Cell Proliferation and TGFbeta-Induced EMT in Ovarian Cancer.
    PLoS One. 2023;18:e0296410.
    >> Share

    January 2022
  29. SENGUPTA D, Ali SN, Bhattacharya A, Mustafi J, et al
    A deep hybrid learning pipeline for accurate diagnosis of ovarian cancer based on nuclear morphology.
    PLoS One. 2022;17:e0261181.
    >> Share

  30. HEITZ F, Lakis S, Harter P, Heikaus S, et al
    Cell-free tumor DNA, CA125 and HE4 for the objective assessment of tumor burden in patients with advanced high-grade serous ovarian cancer.
    PLoS One. 2022;17:e0262770.
    >> Share

  31. MCBRIDE CM, Campbell GP, Zhao J, Pentz RD, et al
    Applying citizen science to engage families affected by ovarian cancer in developing genetic service outreach strategies.
    PLoS One. 2022;17:e0262575.
    >> Share

  32. RUDD ML, Hansen NF, Zhang X, Urick ME, et al
    KLF3 and PAX6 are candidate driver genes in late-stage, MSI-hypermutated endometrioid endometrial carcinomas.
    PLoS One. 2022;17:e0251286.
    >> Share

  33. JUMAAH AS, Al-Haddad HS, McAllister KA, Yasseen AA, et al
    The clinicopathology and survival characteristics of patients with POLE proofreading mutations in endometrial carcinoma: A systematic review and meta-analysis.
    PLoS One. 2022;17:e0263585.
    >> Share

  34. ELSHAMI M, Tuffaha A, Yaseen A, Alser M, et al
    Awareness of ovarian cancer risk and protective factors: A national cross-sectional study from Palestine.
    PLoS One. 2022;17:e0265452.
    >> Share

  35. PETROCCHI S, Ongaro G, Calvello M, Feroce I, et al
    A randomized controlled trial comparing self-referred message to family-referred message promoting men's adherence to evidence-based guidelines on BRCA1/2 germline genetic testing: A registered study protocol.
    PLoS One. 2022;17:e0266327.
    >> Share

  36. ANNONI AM, Longhini C
    Investigating men's motivations to engage in genetic screening for BRCA1 and BRCA2 mutations.
    PLoS One. 2022;17:e0265387.
    >> Share

  37. DING Y, Oliveira-Ferrer L, Vettorazzi E, Legler K, et al
    VEGF-C serum level is associated with response to bevacizumab maintenance therapy in primary ovarian cancer patients.
    PLoS One. 2022;17:e0269680.
    >> Share

  38. HAZAMA Y, Tsujioka T, Kitanaka A, Tohyama K, et al
    Histone deacetylase inhibitor, panobinostat, exerts anti-proliferative effect with partial normalization from aberrant epigenetic states on granulosa cell tumor cell lines.
    PLoS One. 2022;17:e0271245.
    >> Share

  39. DANSONKA-MIESZKOWSKA A, Szafron LA, Kulesza M, Stachurska A, et al
    PROM1, CXCL8, RUNX1, NAV1 and TP73 genes as independent markers predictive of prognosis or response to treatment in two cohorts of high-grade serous ovarian cancer patients.
    PLoS One. 2022;17:e0271539.
    >> Share

  40. ALI FT, Soliman RM, Hassan NS, Ibrahim AM, et al
    Sensitivity and specificity of microRNA-204, CA125, and CA19.9 as biomarkers for diagnosis of ovarian cancer.
    PLoS One. 2022;17:e0272308.
    >> Share

  41. SRIRAMKUMAR S, Metcalfe TX, Lai T, Zong X, et al
    Single-cell analysis of a high-grade serous ovarian cancer cell line reveals transcriptomic changes and cell subpopulations sensitive to epigenetic combination treatment.
    PLoS One. 2022;17:e0271584.
    >> Share

  42. HIEPP L, Mayr D, Gartner K, Schmoeckel E, et al
    Carbonic anhydrase XII as biomarker and therapeutic target in ovarian carcinomas.
    PLoS One. 2022;17:e0271630.
    >> Share

  43. LIU Y, Liu Q, Jiang X
    Bibliometric analysis of hotspots and frontiers in cancer-related fatigue among ovarian cancer survivors.
    PLoS One. 2022;17:e0274802.
    >> Share

  44. HEEMSKERK-GERRITSEN BAM, Hollestelle A, van Asperen CJ, van den Beek I, et al
    Progression-free survival and overall survival after BRCA1/2-associated epithelial ovarian cancer: A matched cohort study.
    PLoS One. 2022;17:e0275015.
    >> Share

  45. SCICCHITANO S, Montalcini Y, Lucchino V, Melocchi V, et al
    Enhanced ZNF521 expression induces an aggressive phenotype in human ovarian carcinoma cell lines.
    PLoS One. 2022;17:e0274785.
    >> Share

  46. DING N, Zhan J, Shi Y, Qiao T, et al
    Obesity in children and adolescents and the risk of ovarian cancer: A systematic review and dose‒response meta-analysis.
    PLoS One. 2022;17:e0278050.
    >> Share

  47. GONZALEZ-BOSQUET J, Weroha SJ, Bakkum-Gamez JN, Weaver AL, et al
    ECPPF (E2F1, CCNA2, POLE, PPP2R1A, FBXW7) stratification: Profiling high-risk subtypes of histomorphologically low-risk and treatment-insensitive endometrioid endometrial cancer.
    PLoS One. 2022;17:e0278408.
    >> Share

  48. DING H, He C, Tong Y, Fang Q, et al
    Cost-effectiveness of PARP inhibitors in malignancies: A systematic review.
    PLoS One. 2022;17:e0279286.
    >> Share

  49. Expression of Concern: The prognostic value of HER2 in ovarian cancer: A meta-analysis of observational studies.
    PLoS One. 2022;17:e0279960.
    >> Share

    January 2021
  50. SATPATHY S, Patra A, Hussain MD, Kazi M, et al
    A fraction of Pueraria tuberosa extract, rich in antioxidant compounds, alleviates ovariectomized-induced osteoporosis in rats and inhibits growth of breast and ovarian cancer cells.
    PLoS One. 2021;16:e0240068.
    >> Share

  51. MOUSTAFA D, Elwahed MRA, Elsaid HH, Parvin JD, et al
    Modulation of Early Mitotic Inhibitor 1 (EMI1) depletion on the sensitivity of PARP inhibitors in BRCA1 mutated triple-negative breast cancer cells.
    PLoS One. 2021;16:e0235025.
    >> Share

  52. YUK JS, Lee B, Kim K, Kim MH, et al
    Incidence and risk of venous thromboembolism according to primary treatment in women with ovarian cancer: A retrospective cohort study.
    PLoS One. 2021;16:e0250723.
    >> Share

  53. ZHANG R, Yang X, Roque DM, Li C, et al
    A novel small molecule LLL12B inhibits STAT3 signaling and sensitizes ovarian cancer cell to paclitaxel and cisplatin.
    PLoS One. 2021;16:e0240145.
    >> Share

  54. ZHANG L, Hu C, Huang Z, Li Z, et al
    In Silico screening of circulating tumor DNA, circulating microRNAs, and long non-coding RNAs as diagnostic molecular biomarkers in ovarian cancer: A comprehensive meta-analysis.
    PLoS One. 2021;16:e0250717.
    >> Share

  55. TOKUNAGA H, Iida K, Hozawa A, Ogishima S, et al
    Novel candidates of pathogenic variants of the BRCA1 and BRCA2 genes from a dataset of 3,552 Japanese whole genomes (3.5KJPNv2).
    PLoS One. 2021;16:e0236907.
    >> Share

  56. PRAHM KP, Hogdall CK, Karlsen MA, Christensen IJ, et al
    MicroRNA characteristics in epithelial ovarian cancer.
    PLoS One. 2021;16:e0252401.
    >> Share

  57. WALSH CS, Kamrava M, Rogatko A, Kim S, et al
    Phase II trial of cisplatin, gemcitabine and pembrolizumab for platinum-resistant ovarian cancer.
    PLoS One. 2021;16:e0252665.
    >> Share

  58. OYAMA Y, Shigeta S, Tokunaga H, Tsuji K, et al
    CHD4 regulates platinum sensitivity through MDR1 expression in ovarian cancer: A potential role of CHD4 inhibition as a combination therapy with platinum agents.
    PLoS One. 2021;16:e0251079.
    >> Share

  59. GUI T, Yao C, Jia B, Shen K, et al
    Identification and analysis of genes associated with epithelial ovarian cancer by integrated bioinformatics methods.
    PLoS One. 2021;16:e0253136.
    >> Share

  60. LOPACINSKA-JORGENSEN J, Oliveira DVNP, Wayne Novotny G, Hogdall CK, et al
    Integrated microRNA and mRNA signatures associated with overall survival in epithelial ovarian cancer.
    PLoS One. 2021;16:e0255142.
    >> Share

  61. PARIS EA, Bahr JM, Bitterman P, Basu S, et al
    Incidence of malignant transformation in the oviductal fimbria in laying hens, a preclinical model of spontaneous ovarian cancer.
    PLoS One. 2021;16:e0255007.
    >> Share

  62. WANG H, Ye F, Zhou C, Cheng Q, et al
    High expression of ENPP1 in high-grade serous ovarian carcinoma predicts poor prognosis and as a molecular therapy target.
    PLoS One. 2021;16:e0245733.
    >> Share

  63. ALKHARUSI A, AlMuslahi A, AlBalushi N, AlAjmi R, et al
    Connections between prolactin and ovarian cancer.
    PLoS One. 2021;16:e0255701.
    >> Share

  64. CIRILLO PDR, Margiotti K, Fabiani M, Barros-Filho MC, et al
    Multi-analytical test based on serum miRNAs and proteins quantification for ovarian cancer early detection.
    PLoS One. 2021;16:e0255804.
    >> Share

  65. STEFANOU DT, Bamias A, Episkopou H, Kyrtopoulos SA, et al
    Correction: Aberrant DNA Damage Response Pathways May Predict the Outcome of Platinum Chemotherapy in Ovarian Cancer.
    PLoS One. 2021;16:e0256051.
    >> Share

  66. MCCORKLE JR, Gorski JW, Liu J, Riggs MB, et al
    Lapatinib and poziotinib overcome ABCB1-mediated paclitaxel resistance in ovarian cancer.
    PLoS One. 2021;16:e0254205.
    >> Share

  67. JAREID M, Snapkov I, Holden M, Busund LR, et al
    The blood transcriptome prior to ovarian cancer diagnosis: A case-control study in the NOWAC postgenome cohort.
    PLoS One. 2021;16:e0256442.
    >> Share

  68. NAPOLI E, Bonsdorff TB, Jorstad IS, Bruland OS, et al
    Radon-220 diffusion from 224Ra-labeled calcium carbonate microparticles: Some implications for radiotherapeutic use.
    PLoS One. 2021;16:e0248133.
    >> Share

  69. HANNA DH, R Saad G
    Induction of mitochondria mediated apoptosis in human ovarian cancer cells by folic acid coated tin oxide nanoparticles.
    PLoS One. 2021;16:e0258115.
    >> Share

  70. HO PJ, Yeoh YS, Miao H, Lim SH, et al
    Cohort profile: The Singapore Breast Cancer Cohort (SGBCC), a multi-center breast cancer cohort for evaluation of phenotypic risk factors and genetic markers.
    PLoS One. 2021;16:e0250102.
    >> Share

  71. MIMOUN C, Paoletti X, Gaillard T, Crestani A, et al
    Using a new diagnostic tool to predict lymph node metastasis in advanced epithelial ovarian cancer leads to simple lymphadenectomy decision rules: A multicentre study from the FRANCOGYN group.
    PLoS One. 2021;16:e0258783.
    >> Share

  72. ANCHOORI RK, George L, Tseng SH, Lam B, et al
    Chirality and asymmetry increase the potency of candidate ADRM1/RPN13 inhibitors.
    PLoS One. 2021;16:e0256937.
    >> Share

  73. SAAVALAINEN L, Lassus H, But A, Gissler M, et al
    Incidence of extraovarian clear cell cancers in women with surgically diagnosed endometriosis: A cohort study.
    PLoS One. 2021;16:e0253270.
    >> Share

  74. KAUR P, Nagar S, Bhagwat M, Uddin M, et al
    Activated heme synthesis regulates glycolysis and oxidative metabolism in breast and ovarian cancer cells.
    PLoS One. 2021;16:e0260400.
    >> Share

  75. WONG DH, Mardock AL, Manrriquez EN, Lai TS, et al
    Trends in extent of surgical cytoreduction for patients with ovarian cancer.
    PLoS One. 2021;16:e0260255.
    >> Share

  76. SAEED-VAFA D, Marchion DC, McCarthy SM, Hakam A, et al
    Utilizing digital pathology to quantify stromal caveolin-1 expression in malignant and benign ovarian tumors: Associations with clinicopathological parameters and clinical outcomes.
    PLoS One. 2021;16:e0256615.
    >> Share

  77. GRESSEL GM, Usyk M, Frimer M, Kuo DYS, et al
    Characterization of the endometrial, cervicovaginal and anorectal microbiota in post-menopausal women with endometrioid and serous endometrial cancers.
    PLoS One. 2021;16:e0259188.
    >> Share

    January 2020
  78. FADDA M, Chappuis PO, Katapodi MC, Pagani O, et al
    Physicians communicating with women at genetic risk of breast and ovarian cancer: Are we in the middle of the ford between contradictory messages and unshared decision making?
    PLoS One. 2020;15:e0240054.
    >> Share

  79. SAGLAM O, Tang Z, Tang G, Medeiros LJ, et al
    KAT6A amplifications are associated with shorter progression-free survival and overall survival in patients with endometrial serous carcinoma.
    PLoS One. 2020;15:e0238477.
    >> Share

  80. SOPO M, Sallinen H, Hamalainen K, Kivela A, et al
    High expression of Tie-2 predicts poor prognosis in primary high grade serous ovarian cancer.
    PLoS One. 2020;15:e0241484.
    >> Share

  81. ESTERMANN M, Huang YL, Septiadi D, Ritz D, et al
    Patient-derived and artificial ascites have minor effects on MeT-5A mesothelial cells and do not facilitate ovarian cancer cell adhesion.
    PLoS One. 2020;15:e0241500.
    >> Share

  82. SIEBENKAS C, Chiappinelli KB, Guzzetta AA, Sharma A, et al
    Correction: Inhibiting DNA methylation activates cancer testis antigens and expression of the antigen processing and presentation machinery in colon and ovarian cancer cells.
    PLoS One. 2020;15:e0243944.
    >> Share

  83. LEANDERSSON P, Akesson A, Hedenfalk I, Malander S, et al
    A multiplex biomarker assay improves the diagnostic performance of HE4 and CA125 in ovarian tumor patients.
    PLoS One. 2020;15:e0240418.
    >> Share

  84. WANG Y, Tao VL, Shin CY, Salamanca C, et al
    Establishment and characterization of VOA1066 cells: An undifferentiated endometrial carcinoma cell line.
    PLoS One. 2020;15:e0240412.
    >> Share

  85. PATRA B, Lateef MA, Brodeur MN, Fleury H, et al
    Carboplatin sensitivity in epithelial ovarian cancer cell lines: The impact of model systems.
    PLoS One. 2020;15:e0244549.
    >> Share

  86. BATES M, Spillane CD, Gallagher MF, McCann A, et al
    The role of the MAD2-TLR4-MyD88 axis in paclitaxel resistance in ovarian cancer.
    PLoS One. 2020;15:e0243715.
    >> Share

Free Medical Abstracts
Privacy Policy

© Amedeo 1997-2016